Information Provided By: 
Fly News Breaks for June 1, 2015
AZN, CLVS
Jun 1, 2015 | 05:59 EDT
Mizuho analyst Peter Lawson raised his price target for Clovis (CLVS) to $103 from $100 and recommends buying the stock on any post-ASCO weakness. Lawson notes that while headline immature progression-free survival declined for Clovis's rociletinib, there was no significant update for AstraZeneca's (AZN) competing inhibitor AZD9291. He believes a "number of discrepancies and a lack of clarity" remain around AZD9291. The analyst keeps a Buy rating on Clovis.
News For CLVS;AZN From the Last 2 Days
AZN
Apr 18, 2024 | 09:41 EDT
Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).
